Results 11 to 20 of about 4,657 (129)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Alzheimer’s Research & Therapy, 2022
Background Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of this analysis is
Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer, Randall J. Bateman   +9 more
doaj   +1 more source

Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer’s disease: A systematic review

International Journal of Immunopathology and Pharmacology, 2023
Background Lecanemab is the latest monoclonal antibody that targets beta-amyloid approved exclusively for treatment of Alzheimer’s disease with mild cognitive impairment or mild dementia.
Selia Chowdhury, Nurjahan Shipa Chowdhury   +1 more
doaj   +1 more source

Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation

Neurology and Therapy, 2023
Introduction Alzheimer’s disease (AD), a neurodegenerative disorder that progresses from mild cognitive impairment (MCI) to dementia, is responsible for significant burden on caregivers and healthcare systems. In this study, data from the large phase III
Ataru Igarashi, Mie Kasai Azuma, Quanwu Zhang, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Kiyoyuki Tomita, Amir Abbas Tahami Monfared   +8 more
doaj   +1 more source

A Path to Improved Alzheimer’s Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer’s Disease from the CLARITY AD Trial

Neurology and Therapy, 2023
Introduction Alzheimer’s disease (AD), a progressive neurodegenerative disease, is the main cause of dementia and one of the leading causes of death for elderly people in the USA.
Amir Abbas Tahami Monfared, Weicheng Ye, Aditya Sardesai, Henri Folse, Ameya Chavan, Elena Aruffo, Quanwu Zhang   +6 more
doaj   +1 more source

Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG

Annals of Clinical and Translational Neurology
Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relatively short half‐life, lecanemab administered as a
Jean‐Pierre Bellier, Andrea M. Román Viera, Caitlyn Christiano, Juliana A. U. Anzai, Stephanie Moreno, Emily C. Campbell, Lucas Godwin, Amy Li, Alan Y. Chen, Sarah M. Alam, Adriana Saba, Han Bin Yoo, Hyun‐Sik Yang, Jasmeer P. Chhatwal, Dennis J. Selkoe, Lei Liu   +15 more
doaj   +1 more source

[¹²⁵I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [¹⁸F]Flotaza and [¹²⁵I]IBETA in Postmortem Human Alzheimer’s Disease

Neurology International
Therapeutic antibodies for reducing Aβ plaque load in Alzheimer’s disease (AD) is currently making rapid progress. The diagnostic imaging of Aβ plaque load in AD has been underway and is now used in clinical studies.
Christopher Liang, Cayz G. Paclibar, Noresa L. Gonzaga, Stephanie A. Sison, Harman S. Bath, Agnes P. Biju, Jogeshwar Mukherjee   +6 more
doaj   +1 more source

Alzheimer's Disease Biomarkers Measured by Capillary Blood Collection Versus Venous Plasma and Cerebrospinal Fluid

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Blood biomarkers are increasingly critical for non‐invasive Alzheimer's Disease (AD) diagnostics and research but typically require on‐site processing. Remote point‐of‐care collection methods could enhance biomarker testing in clinical and research settings.
Sara Ho, Ziling Shen, Alexandria Lewis, Megha Patel, Anny Zheng, Gianna Proscino, Thaovy Ho, Jiangxia Wang, Marilyn Albert, Abhay Moghekar   +9 more
wiley   +1 more source

Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study

Neurology and Therapy
Introduction With the advent of disease-modifying therapies for early Alzheimer’s disease (AD), a comprehensive characterization of patients initiating lecanemab in the USA is needed to understand its use in real-world settings.
Marwan N. Sabbagh, Chenyue Zhao, Malena Mahendran, Se Ryeong Jang, François Laliberté, Hideki Toyosaki, Kaixin Zhang, Feride Frech, Kavita V. Nair   +8 more
doaj   +1 more source

Near‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease

Advanced Science, EarlyView.
Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li   +11 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease

CPT: Pharmacometrics & Systems Pharmacology
Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease upon ...
Oneeb Majid, Youfang Cao, Brian A. Willis, Seiichi Hayato, Osamu Takenaka, Bojan Lalovic, Sree Harsha Sreerama Reddy, Natasha Penner, Larisa Reyderman, Sanae Yasuda, Ziad Hussein   +10 more
doaj   +1 more source